Original Article
Black Cohosh Hepatic Safety: Follow-Up of 107 Patients Consuming a Special Cimicifuga racemosa rhizome Herbal Extract and Review of Literature
Table 1
Baseline characteristics of study participants.
| Characteristics | N = 107 (%) |
| Age | 48 (SD 4.24) | Menopause | | Spontaneous premature | 7 (6.5) | Perimenopause | 29 (27.1) | Menopause from >3 years | 55 (51.4) | Menopause from >6 years | 10 (9.3) | Surgical menopause | 6 (5.6%) | Treatment | | Cimicifuga racemosa herbal extract titrated in 2.5% of actein | 500 mg daily | 49 (45.8) | 500 mg + other plants | 33 (30.9) | 1000 mg daily | 11 (10.3) | 1000 mg + other plants | 14 (13) | Clinical history | | Depression or anxiety | 89 (83.1) | Moderate alcohol consumption | 86 (80.3) | Chronic headaches | 27 (25.2) | Dyspepsia | 16 (15) | Hypertension | 12 (11.2) | Thyroid disease | 8 (7.4) | Hepatobiliary disease | 5 (4.6) | Allergies | 5 (4.6) | Previous cancer non genital organ | 3 (2.8) | Major heart disease | 2 (1.8) | Autoimmunity disease | 1 (0.93) | Major psychiatric diseases | 0 | Alcohol abuse | 0 | Previous idiosyncratic reactions to drugs | 0 | Concomitant medication | | Antacids | 26 (24.3) | NSAID | 25 (23.3) | HRT | 17 (15.9) | Hypotensive | 12 (11.2) | Hormone thyroid therapy | 8 (7.5) | Botanicals | 5 (4.6) | Administration of blood product | 0 | Antiestrogen drugs | 0 | Vitamins | 0 |
|
|